Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
暂无分享,去创建一个
M. Loh | J. Gastier-Foster | N. Heerema | C. Mullighan | B. Wood | J. Easton | S. Hunger | C. Willman | A. Angiolillo | M. Borowitz | M. Valentine | Jinghui Zhang | M. Devidas | A. Carroll | W. Carroll | E. Raetz | Yu Liu | Yongjin Li | R. Harvey | I. Chen | Ying Shao | Amy A. Smith | K. Roberts | Yunfeng Dai | S. Reshmi | K. Rabin | M. Burke | P. Zweidler-McKay | H. Jenkins | T. Tran | W. Salzer | Jonathan V Nguyen | Eileen Stonerock | D. Payne‐Turner | Elizabeth A Raetz | Zhaohui Gu | Shalini C Reshmi | Nyla A Heerema | Michael J Borowitz | Anne L Angiolillo | Wanda L Salzer | Patrick A Zweidler-McKay | Charles G Mullighan | Julie M Gastier-Foster | Stephen P Hunger | B. Wood | M. Loh
[1] S. Izraeli,et al. BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options. , 2017, Blood reviews.
[2] C. Bloomfield,et al. High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Loh,et al. Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2017, Blood.
[4] Guido Marcucci,et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.
[5] Heather L. Mulder,et al. Deregulation of DUX4 and ERG in acute lymphoblastic leukemia , 2016, Nature Genetics.
[6] C. Harrison,et al. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. , 2016, Blood.
[7] M. Loh,et al. Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia. , 2016, Cancer cell.
[8] K. Horibe,et al. Identification of novel kinase fusion transcripts in paediatric B cell precursor acute lymphoblastic leukaemia with IKZF1 deletion , 2015, British journal of haematology.
[9] W. Evans,et al. BCR-ABL1-like cases in pediatric acute lymphoblastic leukemia: a comparison between DCOG/Erasmus MC and COG/St. Jude signatures , 2015, Haematologica.
[10] J. Downing,et al. Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Loh,et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. , 2015, Blood.
[12] A. Letai,et al. Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. , 2015, Cancer cell.
[13] M. D. Den Boer,et al. Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates , 2015, Haematologica.
[14] C. Mullighan,et al. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. , 2015, Blood.
[15] N. Kiyokawa,et al. TKI dasatinib monotherapy for a patient with Ph‐like ALL bearing ATF7IP/PDGFRB translocation , 2015, Pediatric blood & cancer.
[16] M. D. Den Boer,et al. The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia. , 2015, Blood.
[17] O. Kallioniemi,et al. FusionCatcher – a tool for finding somatic fusion genes in paired-end RNA-sequencing data , 2014, bioRxiv.
[18] P. Brown,et al. The Biology and Targeting of FLT3 in Pediatric Leukemia , 2014, Front. Oncol..
[19] J. Downing,et al. Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Heather L. Mulder,et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.
[21] R. Wade,et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. , 2014, Blood.
[22] R. Wade,et al. IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] N. Heerema,et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 , 2014, Leukemia.
[24] M. Stratton,et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia , 2014, Nature Genetics.
[25] Michael C. Rusch,et al. Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (“Ph-like” or “BCR-ABL1-Like”) Signature For Therapeutic Targeting and Clinical In , 2013 .
[26] W. Evans,et al. Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL. , 2013, Blood.
[27] C. Mullighan,et al. Tyrosine kinase inhibitor therapy induces remission in a patient with refractory EBF1-PDGFRB-positive acute lymphoblastic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Loh,et al. Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. , 2013, Blood.
[29] M. Loh,et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. , 2012, Blood.
[30] O. Haas,et al. Treatment outcome of CRLF2 ‐rearranged childhood acute lymphoblastic leukaemia: a comparative analysis of the AIEOP‐BFM and UK NCRI‐CCLG study groups , 2012, British journal of haematology.
[31] G. Lucchini,et al. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study , 2012, The Lancet. Oncology.
[32] Ryan D. Morin,et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. , 2012, Cancer cell.
[33] Michael N. Edmonson,et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2011, Blood.
[34] M. Muckenthaler,et al. Gain-of-function mutations in interleukin-7 receptor-α (IL7R) in childhood acute lymphoblastic leukemias , 2011, The Journal of experimental medicine.
[35] Kevin K Dobbin,et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. , 2010, Blood.
[36] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[37] M. DePristo,et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.
[38] J. Downing,et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.
[39] Takashi Akasaka,et al. Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.
[40] E. Domany,et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group. , 2010, Blood.
[41] J. Downing,et al. Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia , 2009, Nature Genetics.
[42] N. Heerema,et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Takashi Akasaka,et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. , 2009, Blood.
[44] S. Luo,et al. Chimeric transcript discovery by paired-end transcriptome sequencing , 2009, Proceedings of the National Academy of Sciences.
[45] M. Loh,et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.
[46] O. Bernard,et al. A novel translocation, t(14;19)(q32;p13), involving IGH@ and the cytokine receptor for erythropoietin , 2009, Leukemia.
[47] W. Evans,et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.
[48] Lee T. Sam,et al. Transcriptome Sequencing to Detect Gene Fusions in Cancer , 2009, Nature.
[49] S. Hunger,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. , 2008, Blood.
[50] R. Tibshirani,et al. Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[51] R. Arceci. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study , 2012 .
[52] A. Iwama,et al. Identification of a novel TEL–Lyn fusion gene in primary myelofibrosis , 2010, Leukemia.
[53] J. Stockman. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome , 2010 .
[54] R. Arceci. Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia , 2010 .